The US Food and Drug Administration turned down a self-administered version of AstraZeneca Plc’s lupus medicine, but the UK drugmaker said it’s still working with regulators to advance the request.
Astra provided the information the FDA requested in a complete response letter and will work to “progress the application as quickly as possible,” it said Tuesday. The stock fell as much as 1.9% in early London trading, almost wiping out its gains for the year.
The medicine, Saphnelo, is already approved as an intravenous treatment, meaning it has to be injected in a vein and requires going to ...
